Actively Recruiting
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Led by Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Updated on 2025-01-01
50
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
GVHD prevention using a combination of post-transplantation cyclophosphamide in combination with abatacept, vedolizumab and Ruxolitinib in children and young adults with hematoloblastosis after myeloablative conditioning regimen with treosulfan/TBI, etoposide, fludarabine after HSCT from matched unrelated and haploidentical donors
CONDITIONS
Official Title
Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients under 21 years old with acute lymphoblastic leukemia, myeloblastic leukemia, biphenotypic leukemia, bilinear leukemia, malignant lymphoma, or myelodysplastic syndrome
You will not qualify if you...
- Age over 21 years
- Patients with acute lymphoblastic leukemia outside clinical and hematological remission
- Lansky/Karnowski index less than 70%
- Heart function with left ventricular ejection fraction below 40%
- Kidney function with creatinine clearance less than 70 ml/min
- Liver function with total bilirubin, ALT, AST, or ALP above twice the normal levels
- Lung capacity below 50% or oxygen saturation below 92% in children unable to perform lung function tests
- Uncontrolled viral, fungal, or bacterial infection
- Mental illness in patient or caregiver impairing study participation or compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov
Moscow, Russia, 117198
Actively Recruiting
Research Team
M
Maschan Michael,, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here